Short-term effectiveness of single-dose intranasal spray COVID-19 vaccine against symptomatic SARS-CoV-2 Omicron infection in healthcare workers: a prospective cohort study DOI Creative Commons

Hongfei Mi,

Qi Chen, Hongyan Lin

и другие.

EClinicalMedicine, Год журнала: 2023, Номер 67, С. 102374 - 102374

Опубликована: Дек. 13, 2023

The pivotal phase 3 efficacy clinical trial has demonstrated that a two-dose regimen of dNS1-RBD (Beijing Wantai Biological Pharmacy Enterprise, Beijing, China) is well-tolerated and provides wide protection against SARS-CoV-2 infection. However, the effectiveness single-dose still unknown. We aimed to estimate one-dose symptomatic Omicron infections in real-world conditions.

Язык: Английский

How effective is the BNT162b2 mRNA vaccine against SARS-CoV-2 transmission and infection? A national programme analysis in Monaco, July 2021 to September 2022 DOI Creative Commons
Thomas Althaus, Christopher E. Overton,

Isabelle Devaux

и другие.

BMC Medicine, Год журнала: 2024, Номер 22(1)

Опубликована: Июнь 5, 2024

Abstract Background We quantified SARS-CoV-2 dynamics in different community settings and the direct indirect effect of BNT162b2 mRNA vaccine Monaco for variants concern (VOC). Methods Between July 2021 September 2022, we prospectively investigated 20,443 contacts from 6320 index cases using data COVID-19 Public Health Programme. calculated secondary attack rates (SARs) households ( n = 13,877), schools 2508) occupational 6499) settings. used binomial regression with a complementary log–log link function to measure adjusted hazard ratios (aHR) effectiveness (aVE) infect be infected households. Results In households, SAR was 55% (95% CI 54–57) 50% (48–51) among unvaccinated vaccinated contacts, respectively. The 32% (28–36) 12% (10–13) workplaces, 7% (6–9) 6% (3–10) schools, household, aHR lower than (aHR 0.68 [0.55–0.83] 0.93 [0.74–1.1] delta; 0.73 [0.66–0.81] 0.89 [0.80–0.99] omicron BA.1&2, respectively). Vaccination had no significant on either or aVE BA.4&5. (17, 45) 27% (19, 34), (− 17, 26) 11% (1, 20) delta greatest previous infection single dose during BA.1&2 period (45% [27, 59]), while lowest were found three doses (aVE − 24% [− 63, 6]) one 36% 198, 38]) BA.4&5 period. Conclusions Protection conferred by against transmission low regardless number infection. There authorities carrying out vaccination campaigns should bear mind that current generation vaccines may not represent an effective tool protecting individuals transmitting acquiring

Язык: Английский

Процитировано

3
Oral delivery of a chitosan adjuvanted COVID-19 vaccine provides long-lasting and broad-spectrum protection against SARS-CoV-2 variants of concern in golden hamsters DOI
Shen Wang, Huan Cui, Cheng Zhang

и другие.

Antiviral Research, Год журнала: 2023, Номер 220, С. 105765 - 105765

Опубликована: Ноя. 28, 2023

Язык: Английский

Процитировано

8
Progress and challenges in the clinical evaluation of immune responses to respiratory mucosal vaccines DOI Creative Commons

Xuanxuan Zhang,

Jialu Zhang, Si Chen

и другие.

Expert Review of Vaccines, Год журнала: 2024, Номер 23(1), С. 362 - 370

Опубликована: Март 6, 2024

Following the coronavirus disease pandemic, respiratory mucosal vaccines that elicit both and systemic immune responses have garnered increasing attention. However, human physiological characteristics pose significant challenges in evaluation of immunity, which directly impedes development application vaccines.

Язык: Английский

Процитировано

2
COVID-19 mRNA vaccines induce robust levels of IgG but limited amounts of IgA within the oronasopharynx of young children DOI Creative Commons
Ying Tang, Brittany P. Boribong, Zoe Swank

и другие.

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Апрель 16, 2024

Understanding antibody responses to SARS-CoV-2 vaccination is crucial for refining COVID-19 immunization strategies. Generation of mucosal immune responses, including IgA, could be potential benefit vaccine efficacy, yet limited evidence exists regarding the production antibodies following administration current mRNA vaccines young children.

Язык: Английский

Процитировано

2
Short-term effectiveness of single-dose intranasal spray COVID-19 vaccine against symptomatic SARS-CoV-2 Omicron infection in healthcare workers: a prospective cohort study DOI Creative Commons

Hongfei Mi,

Qi Chen, Hongyan Lin

и другие.

EClinicalMedicine, Год журнала: 2023, Номер 67, С. 102374 - 102374

Опубликована: Дек. 13, 2023

The pivotal phase 3 efficacy clinical trial has demonstrated that a two-dose regimen of dNS1-RBD (Beijing Wantai Biological Pharmacy Enterprise, Beijing, China) is well-tolerated and provides wide protection against SARS-CoV-2 infection. However, the effectiveness single-dose still unknown. We aimed to estimate one-dose symptomatic Omicron infections in real-world conditions.

Язык: Английский

Процитировано

6